ketoconazole has been researched along with tivozanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Cotreau, MM; Miller, J; Siebers, NM; Slichenmyer, W; Strahs, AL | 1 |
1 review(s) available for ketoconazole and tivozanib
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for ketoconazole and tivozanib
| Article | Year |
|---|---|
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Area Under Curve; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Female; Half-Life; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; United States; Young Adult | 2015 |